Janssen and Genentech will enter clin­i­cal col­lab­o­ra­tion to assess dual mono­clonal anti­body (mAb) combi­na­tion ther­apy

Raritan, NJ (Press Release) – Janssen Research & Development, LLC announced today it has entered into a clin­i­cal trial col­lab­o­ra­tion agree­ment with Genentech, a member of the Roche Group, to ini­ti­ate two studies to de­ter­mine the safety and tolerability of dara­tu­mu­mab (DARZALEX®), the first CD38-directed mono­clonal anti­body (mAb), in combi­na­tion with atezo­lizu­mab, an investi­ga­tional mAb designed to bind with a protein called pro­grammed cell death-ligand 1 (PD-L1). These studies will assess the poten­tial of the combi­na­tion ther­apy in multiple myeloma and in solid tumor. Atezolizumab is cur­rently in devel­op­ment by Roche. Janssen …

• Phase Ib studies of dara­tu­mu­mab in com­bi­na­tion with Roche’s immune checkpoint inhibitor atezo­lizu­mab in a solid tumor and multiple myeloma to be started
• Studies conducted under a clin­i­cal trial col­lab­o­ra­tion agree­ment be­tween Janssen and Roche

Copenhagen, Denmark (Press Release) – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that dara­tu­mu­mab will be in­ves­ti­gated in early stage clin­i­cal studies in com­bi­na­tion with atezo­lizu­mab (anti-PD-L1 anti­body), in a solid tumor and multiple myeloma. The studies will be conducted under a clin­i­cal trial col­lab­o­ra­tion agree­ment be­tween Genmab’s licensing partner for dara­tu­mu­mab, Janssen Biotech, Inc., and Genentech, a member of the Roche Group. Atezolizumab is an inves­ti­ga­tional mono­clonal anti­body de­signed to bind to a protein called PD-L1, which is ex­pressed on tumor cells and …

Findings Presented at the 57th American Society of Hematology Annual Meeting Demonstrate Activity of KEYTRUDA Therapy in Previously-Treated Multiple Myeloma Patients When Combined with Lena­lido­mide and Dexamethasone

Kenilworth, NJ (Press Release) – Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today new study findings investigating the use of KEYTRUDA® (pem­bro­lizu­mab), the com­pany’s anti-PD-1 ther­apy, in com­bi­na­tion with lena­lido­mide and low-dose dexa­meth­a­sone (two com­monly used treat­ments for multiple myeloma) in patients whose dis­ease has progressed after at least two lines of prior ther­apy, in­clud­ing a pro­te­a­some inhibitor and an IMiD (immune modulatory drug). The initial findings from the ongoing Phase 1 KEYNOTE-023 study showed an over­all response rate (ORR) of 76 per­cent (n=13/17), as assessed by …